Jacksonville, FL – April 10, 2026 – Johnson & Johnson today announced that TECNIS Eyhance intraocular lens (IOL), the industry’s first enhanced monofocal IOL[8,] has now been implanted in more than 10 million eyes globally[1], reinforcing its position as the established market leader in the enhanced monofocal category.[2-3]
As cataract surgeons continue to seek technologies that meet growing patient expectations for intermediate vision without compromising distance clarity, TECNIS Eyhance IOL stands apart as the most clinically validated and fastest growing solution in the category it created.[2,4]
“Reaching over 10 million implants is not just a volume milestone—It is validation that TECNIS Eyhance IOL delivers consistent, real-world outcomes at scale,” said Paul Lisenby, Global Head of R&D, Vision, Johnson & Johnson. “That level of adoption reflects years of clinical evidence, surgeon trust, and performance under everyday visual conditions.”[1]
A Category-Defining Innovation with Proven Staying Power
Since its global introduction in 2019, TECNIS Eyhance IOL has transformed expectations for monofocal lenses by slightly extending the depth of focus, while preserving monofocal-like distance quality and image contrast, day and night.*³⁻⁵ Unlike other market options supported primarily by early optical modeling, TECNIS Eyhance IOL is backed by the highest quality and quantity of published clinical evidence across diverse patient populations and real-world practice settings.[4,9-10]
Clinical Performance That Translates Clearly to Patients and Surgeons
Built on the trusted TECNIS platform—celebrating more than 25 years of use in ophthalmology—TECNIS Eyhance IOL slightly extends depth of focus through a continuous increase in power while maintaining high quality distance vision.[*5-7]
What the clinical evidence shows:
- >26 studies demonstrating excellent contrast sensitivity, and some studies in low-light conditions[9,11]
- >48 studies demonstrating intermediate vision capabilities[4,9,13]
- >20 studies demonstrating TECNIS Eyhance IOL patients reporting low instances of visual disturbances (e.g., halos, starbursts, glare) [9,12]
TECNIS Eyhance IOL is part of the industry-leading TECNIS platform, combining advanced optics with proprietary material. The TECNIS portfolio also includes the new TECNIS PureSee IOL, a purely refractive EDOF IOL[14] and TECNIS Odyssey IOL, a Full Visual Range (FVR) IOL[15]. Johnson & Johnson will present new data on TECNIS PureSee IOL and TECNIS Odyssey IOL at ASCRS 2026.
For more patient information and tools please visit www.jjvision.com. Visit us at jnjvisionpro.com/en-us/ and follow Johnson & Johnson | Vision on LinkedIn.
INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS EYHANCE™ and TECNIS EYHANCE™
Toric II IOLs
Rx Only
INDICATIONS FOR USE
The TECNIS EYHANCE IOL, Model ICB00 is indicated for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag.
The TECNIS EYHANCE Toric II IOLs, Models ICU150-ICU600, are indicated for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag.
WARNINGS
Physicians considering lens implantation should weigh the potential risk/benefit ratio for any conditions described in the Directions for Use that could increase complications or impact patient outcomes. The lens should be placed entirely in the capsular bag. Do not place the lens in the ciliary sulcus. Rotation of the TECNIS EYHANCE Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation.
PRECAUTIONS
The safety and effectiveness of the TECNIS EYHANCE IOL has not been substantiated in clinical trials and the effects of the optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically. Do not resterilize the intraocular lens. Do not soak or rinse the intraocular lens with any solution other than sterile balanced salt solution or sterile normal saline. Do not store the intraocular lens in direct sunlight or at a temperature greater than 45°C (113°F). Do not autoclave the intraocular lens. Do not re-use the intraocular lens.
ADVERSE EVENTS
The most frequently reported cumulative adverse event that occurred during the SENSAR™ 1-Piece IOL clinical trial was cystoid macular edema which occurred at a rate of 3.3%.
ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on X, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to
innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TECNIS Eyhance IOL. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
©Johnson & Johnson and its affiliates 2026. All rights reserved.
2026PP08951
Third party trademarks are the property of their respective owners.